Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | SRI SAI AGENCIES | 1 | ₹4.1 L |
| 2 | Schedule 2 | MODERN MEDICAL HALL | 1 | ₹3.3 L |
| 3 | Schedule 3 | MODERN MEDICAL HALL | 1 | ₹5.7 L |
| 4 | Schedule 4 | ALBINO LIFESCIENCES PRIVATE LIMITED | 1 | ₹15.0 L |
| 5 | Schedule 5 | MEDIKON INDIA PRIVATE LIMITED | 1 | ₹8.5 L |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
26 Jun 2026, 3:00 pmClosed
Drug and Consumable
9446681
GEM/2026/B/7645016
Two Packet Bid
Inj Eculizumab 300 mg,Inj Tremelimumab 300 mg,Inj Tislelizumab 100 mg,Tab Ivosidenib 250 mg,Inj Hum
Gurdaspur, Punjab
Item wise evaluation
BOQ
7 documents required · 7 mandatory
3 yrs
₹15 L
₹40 L
10%
Exempted
Yes
26 Jun 2026
16 Jun 2026
26 Jun 2026
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|
| 1 | Inj Eculizumab 300 mg | 6 | Amp or Vial | jatinder@1234 | 30 |
| 2 | Inj Tremelimumab 300 mg | 1 | Amp or Vial | jatinder@1234 | 30 |
| 3 | Inj Tislelizumab 100 mg | 12 | Amp or Vial | jatinder@1234 | 30 |
| 4 | Tab Ivosidenib 250 mg | 180 | No | jatinder@1234 | 30 |
| 5 | Inj Human Insulin Analog Aspart 30 per 70 | 900 | Amp or Vial | jatinder@1234 | 30 |
| 6 | Inj Human Growth Hormone 36 IU, 12 mg per ml | 12 | Amp or Vial | jatinder@1234 | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9446681.pdf
GEM_BID • 0.14 MB
specifications_2026-06-10-11-08-36_b652261a03c564ff78b6b1598f3757e5.pdf
BOQ • 2.04 MB
boq_item_sample_file_2026-06-10-11-08-36_3af0972a7158803f209ebdb2b0792960.csv
BOQ • 0.00 MB
complia_80e1144d-c846-46c6-914e1781074187114_drsharadkumargoel.pdf
GEM_OTHER • 0.05 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at [email protected].